Mosqitter expands mosquito monitoring network with Febris platform

Mosqitter, a Pennsylvania-based startup, is converting its mosquito traps into an AI-driven monitoring network and says it now operates over 5,000 devices across five continents.

The company presented the system publicly at TechCrunch Disrupt 2026, where executives described a device family that captures female mosquitoes without using chemical insecticides and feeds images into a machine-learning pipeline to classify species and flag trends.

According to Mosqitter’s leadership, the hardware imitates human cues — heat, scent and, in the Grand model, released carbon dioxide — to attract egg-laying female mosquitoes.

The company’s co-founder and CEO, Anastasiia Romanova, and co-founder and COO, Olga Diachuk, told reporters that the Grand model combines CO2 release with imaging and AI to improve capture rates and species identification. Mosqitter traces its R&D back to 2019 in Ukraine and lists 2021 as its go-to-market year.

Company statements in the reporting say the installed base has grown sharply from just over 250 units in 2022 to above 5,000 today, and that Mosqitter is pursuing business-to-business distribution partners, especially those with existing government and retail channels.

The startup frames its product as offering public-health value by delivering higher-frequency, species-specific data to spot emerging disease risks earlier; the reporting cites World Health Organization figures showing reported global dengue cases rose from 6.5 million in 2023 to 14.6 million in 2024 as the near-term disease context Mosqitter uses to make that case.

Mosqitter’s executives described the AI decision pathway in accessible terms, with one account likening an internal multi-step classification pipeline to “three judges” reaching a verdict, where a neural network performs initial image analysis followed by additional steps to produce a species call.

Financially, Mosqitter’s founders told TechCrunch they expect revenue growth, with Romanova saying the company is on track to generate more than $1 million in revenue in 2026. The reporting also notes the company is explicitly seeking partners to scale distribution internationally and to sell into institutional and retail channels.

Independent verification of the system’s species-identification accuracy, the operational coverage that 5,000 devices deliver for public-health agencies, and third-party validation of claimed capture-rate gains were not provided in the articles.

Mosqitter’s public statements supply the device counts, commercial plans and technical descriptions cited here; the reporting does not include peer-reviewed validation studies or independent field trials published by third parties.

Mosqitter’s pitch to partners and public-health authorities rests on the premise that catching female mosquitoes at egg-laying moments can reduce future population growth; company executives described that capture-timing strategy as a design objective but the reporting does not include field results quantifying population-level impacts.

The articles document the company’s product features, growth in deployed units, founders’ statements about revenue targets and the WHO dengue figures they cite as rationale for accelerating monitoring capabilities.